CTLA4 and lung carcinoma: Ipilimumab, a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has been explored in combination with other immune checkpoint inhibitors like nivolumab for the treatment of lung cancer, but its use as monotherapy is less common.